Articles published by Ardelyx, Inc.
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
February 27, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
December 20, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
November 21, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 15, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Announces Departure of Board Member
November 13, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 10, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 31, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
October 30, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
October 04, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Tenapanor for Hyperphosphatemia Approved in Japan
September 25, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 11, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
September 07, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 02, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
July 27, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers
ARDX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free